146 related articles for article (PubMed ID: 35201650)
21. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres.
Ragni MV; Fogarty PJ; Josephson NC; Neff AT; Raffini LJ; Kessler CM
Haemophilia; 2012 Jan; 18(1):63-8. PubMed ID: 21539695
[TBL] [Abstract][Full Text] [Related]
22. Real-world resource use and costs of haemophilia A-related bleeding.
Shrestha A; Eldar-Lissai A; Hou N; Lakdawalla DN; Batt K
Haemophilia; 2017 Jul; 23(4):e267-e275. PubMed ID: 28574162
[TBL] [Abstract][Full Text] [Related]
23. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
[TBL] [Abstract][Full Text] [Related]
24. Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia.
Lim CC; Siow B; Choo JCJ; Chawla M; Chin YM; Kee T; Lee PH; Foo M; Tan CS
Int Urol Nephrol; 2019 Jun; 51(6):995-1004. PubMed ID: 31028561
[TBL] [Abstract][Full Text] [Related]
25. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
26. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
[TBL] [Abstract][Full Text] [Related]
27. Haemophilia in Côte d'Ivoire (the Ivory Coast) in 2017: Extensive data collection as part of the World Federation of Hemophilia's twinning programme.
Lambert C; Meité N; Sanogo I; Lobet S; Adjambri E; Eeckhoudt S; Hermans C
Haemophilia; 2019 Mar; 25(2):236-243. PubMed ID: 30748057
[TBL] [Abstract][Full Text] [Related]
28. 1-Deamino-8-D-arginine-vasopressin--an alternative in the management of mild haemophilia A and von Willebrand's disease.
Niessner H; Korninger C
Wien Klin Wochenschr; 1983 Nov; 95(21):753-7. PubMed ID: 6424339
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patients.
Mariana G; Ciavarella N; Mazzucconi MG; Antoncecchi S; Solinas S; Ranieri P; Pettini P; Agrestini F; Mandelli F
Clin Lab Haematol; 1984; 6(3):229-38. PubMed ID: 6440729
[TBL] [Abstract][Full Text] [Related]
30. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
[TBL] [Abstract][Full Text] [Related]
31. [Prevention of joint damage in hemophilic children with early prophylaxis].
Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
[TBL] [Abstract][Full Text] [Related]
32. Desmopressin in non-severe haemophilia A: Test-response and clinical outcomes in a single Canadian centre review.
Hews-Girard J; Rydz N; Lee A; Goodyear MD; Poon MC
Haemophilia; 2018 Sep; 24(5):720-725. PubMed ID: 30004154
[TBL] [Abstract][Full Text] [Related]
33. Objective quantification of adherence to prophylaxis in haemophilia patients aged 12 to 25years and its potential association with bleeding episodes.
Pérez-Robles T; Romero-Garrido JA; Rodriguez-Merchan EC; Herrero-Ambrosio A
Thromb Res; 2016 Jul; 143():22-7. PubMed ID: 27172834
[TBL] [Abstract][Full Text] [Related]
34. Mild bleeding disorders: review of 120 patients.
Bolton-Maggs P; Wilkinson LS
Clin Lab Haematol; 1984; 6(3):247-56. PubMed ID: 6335071
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
36. Haematuria is not a risk factor of hypertension or renal impairment in patients with haemophilia.
Sun HL; Yang M; Sait AS; von Drygalski A; Jackson S
Haemophilia; 2016 Jul; 22(4):549-55. PubMed ID: 27030081
[TBL] [Abstract][Full Text] [Related]
37. The natural history of mild haemophilia: a 30-year single centre experience.
Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
[TBL] [Abstract][Full Text] [Related]
38. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
[TBL] [Abstract][Full Text] [Related]
39. Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices.
Liu W; Xue F; Poon MC; Chen L; Jin Z; Zhang L; Yang R
Br J Haematol; 2021 Aug; 194(4):750-758. PubMed ID: 34340252
[TBL] [Abstract][Full Text] [Related]
40. Clotting factor activity levels and bleeding risk in people with haemophilia playing sports.
Versloot O; Kemler E; Blokzijl J; Timmer M; Schuuring M; van Galen KPM; Kremer Hovinga ICL; van der Valk PR; van Vulpen LFD; Schutgens REG; van Koppenhagen CF; van der Net J; Fischer K
Haemophilia; 2023 Jul; 29(4):1013-1023. PubMed ID: 37224272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
